Zacks Research Analysts Reduce Earnings Estimates for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Equities research analysts at Zacks Research decreased their Q1 2026 earnings estimates for Eli Lilly and Company in a research note issued on Wednesday, April 17th. Zacks Research analyst K. Shah now forecasts that the company will earn $6.06 per share for the quarter, down from their previous forecast of $6.11. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.52 per share. Zacks Research also issued estimates for Eli Lilly and Company’s FY2026 earnings at $24.44 EPS.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.09 earnings per share.

Several other brokerages have also weighed in on LLY. Bank of America increased their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday, April 15th. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research report on Wednesday, February 21st. Finally, BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Price Performance

Shares of LLY opened at $726.31 on Friday. The firm has a market capitalization of $690.11 billion, a PE ratio of 125.23, a PEG ratio of 1.64 and a beta of 0.34. The company’s 50-day moving average is $763.96 and its 200-day moving average is $659.59. Eli Lilly and Company has a fifty-two week low of $369.76 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds have recently made changes to their positions in LLY. Fairfield Bush & CO. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $107,000. Roundview Capital LLC boosted its position in Eli Lilly and Company by 2.6% during the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after buying an additional 53 shares during the period. Merit Financial Group LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $210,000. NewEdge Advisors LLC boosted its position in Eli Lilly and Company by 9.9% during the 1st quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after buying an additional 4,774 shares during the period. Finally, Barometer Capital Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $561,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.